Genmab — August 2013
-
Fase 2 ofatumumab i behandlingsrefraktær DLCBL
: http://onlinelibrary.wiley.com/doi/10.1111/bjh.12537/full -
DLCBL studiet er det studie der fejlede i 2010, gad vide hvordor det havner i British Journal og hematholgy nu??
-
fejlede forsøg kan bære ligeså meget videnskabelig relevans som mislykkedes
-
Det var nu mere tidspunktet jeg studsede over, artikel
3 år efter resultater -
https://www.landesbioscience.com/article/26233/full_text/#load/info/all ... Produktion af bispec. Antibodies
-
Daratumumab.
Anti-CD38 monoclonal antibody, Treatment of multiple myeloma.
Richardson, P., Lokhorst, H., Palumbo, A., Nahi, H., Laubach, J., Gimsing, P., Lisby, S., Cakana, A., Constantin Brun, N., Plesner, T.
Drugs Fut 2013, 38(8): 535
Summary | Full Text: PDF -
http://finance.yahoo.com/q?s=GNMSF 10.000 stk. Det ser ud til at være JP.Morgan der køber de rigtige Genmab i Kbh. De tegner sig for en pæn volumen historisk set indenfor den seneste tid.
-
den danser sådan ret meget frem og tilbage. men virker ret stabil i 160-170 området
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind